<?xml version='1.0' encoding='utf-8'?>
<document id="27428445"><sentence text="Potentially severe drug-drug interactions among older people and associations in assisted living facilities in Finland: a cross-sectional study." /><sentence text="This study aims to assess potentially severe class D drug-drug interactions (DDDIs) in residents 65 years or older in assisted living facilities with the use of a Swedish and Finnish drug-drug interaction database (SFINX)" /><sentence text="" /><sentence text="A cross-sectional study of residents in assisted living facilities in Helsinki, Finland" /><sentence text="" /><sentence text="A total of 1327 residents were assessed in this study" /><sentence text=" Drugs were classified according to the Anatomical Therapeutic Chemical (ATC) classification system and DDDIs were coded according to the SFINX" /><sentence text="" /><sentence text="Prevalence of DDDIs, associated factors and 3-year mortality among residents" /><sentence text="" /><sentence text="Of the participants (mean age was 82" /><sentence text="7 years, 78" /><sentence text="3% were females), 5" /><sentence text="9% (N = 78) are at risk for DDDIs, with a total of 86 interactions" /><sentence text=" Participants with DDDIs had been prescribed a higher number of drugs (10" /><sentence text="8 (SD 3" /><sentence text="8) vs" /><sentence text=" 7" /><sentence text="9 (SD 3" /><sentence text="7), p &lt; 0" /><sentence text="001)" /><sentence text=" A larger proportion of residents with DDDIs suffered from rheumatoid arthritis or osteoarthritis than those not exposed to DDDIs (24" /><sentence text="7% vs" /><sentence text=" 15" /><sentence text="4%, p = 0" /><sentence text="030)" /><sentence text=" The most frequent DDDIs were related to the concomitant use of potassium with amiloride (N = 12) or spironolactone (N = 12)"><entity charOffset="64-73" id="DDI-PubMed.27428445.s27.e0" text="potassium" /><entity charOffset="79-88" id="DDI-PubMed.27428445.s27.e1" text="amiloride" /><entity charOffset="101-115" id="DDI-PubMed.27428445.s27.e2" text="spironolactone" /><pair ddi="false" e1="DDI-PubMed.27428445.s27.e0" e2="DDI-PubMed.27428445.s27.e0" /><pair ddi="false" e1="DDI-PubMed.27428445.s27.e0" e2="DDI-PubMed.27428445.s27.e1" /><pair ddi="false" e1="DDI-PubMed.27428445.s27.e0" e2="DDI-PubMed.27428445.s27.e2" /><pair ddi="false" e1="DDI-PubMed.27428445.s27.e1" e2="DDI-PubMed.27428445.s27.e1" /><pair ddi="false" e1="DDI-PubMed.27428445.s27.e1" e2="DDI-PubMed.27428445.s27.e2" /></sentence><sentence text=" Carbamazepine (N = 13) and methotrexate (N = 9) treatments were also frequently linked to DDDIs"><entity charOffset="1-14" id="DDI-PubMed.27428445.s28.e0" text="Carbamazepine" /><entity charOffset="28-40" id="DDI-PubMed.27428445.s28.e1" text="methotrexate" /><pair ddi="false" e1="DDI-PubMed.27428445.s28.e0" e2="DDI-PubMed.27428445.s28.e0" /><pair ddi="false" e1="DDI-PubMed.27428445.s28.e0" e2="DDI-PubMed.27428445.s28.e1" /></sentence><sentence text=" During the follow-up, no differences in mortality emerged between the participants exposed to DDDIs and the participants not exposed to DDDIs" /><sentence text="" /><sentence text="Of the residents in assisted living, 5" /><sentence text="9% were exposed to DDDIs associated with the use of a higher number of drugs" /><sentence text=" Physicians should be trained to find safer alternatives to drugs associated with DDDIs" /><sentence text=" KEY POINTS   Potentially severe, class D drug-drug interactions (DDDIs) have been defined in the SFINX database as clinically relevant drug interactions that should be avoided" /><sentence text="  • Of the residents in assisted living, 5" /><sentence text="9% were exposed to DDDIs that were associated with the use of a higher number of drugs" /><sentence text="  • The most frequent DDDIs were related to the concomitant use of potassium with amiloride or spironolactone"><entity charOffset="67-76" id="DDI-PubMed.27428445.s37.e0" text="potassium" /><entity charOffset="82-91" id="DDI-PubMed.27428445.s37.e1" text="amiloride" /><entity charOffset="95-109" id="DDI-PubMed.27428445.s37.e2" text="spironolactone" /><pair ddi="false" e1="DDI-PubMed.27428445.s37.e0" e2="DDI-PubMed.27428445.s37.e0" /><pair ddi="false" e1="DDI-PubMed.27428445.s37.e0" e2="DDI-PubMed.27428445.s37.e1" /><pair ddi="false" e1="DDI-PubMed.27428445.s37.e0" e2="DDI-PubMed.27428445.s37.e2" /><pair ddi="false" e1="DDI-PubMed.27428445.s37.e1" e2="DDI-PubMed.27428445.s37.e1" /><pair ddi="false" e1="DDI-PubMed.27428445.s37.e1" e2="DDI-PubMed.27428445.s37.e2" /></sentence><sentence text=" Carbamazepine and methotrexate were also linked to DDDIs"><entity charOffset="1-14" id="DDI-PubMed.27428445.s38.e0" text="Carbamazepine" /><entity charOffset="19-31" id="DDI-PubMed.27428445.s38.e1" text="methotrexate" /><pair ddi="false" e1="DDI-PubMed.27428445.s38.e0" e2="DDI-PubMed.27428445.s38.e0" /><pair ddi="false" e1="DDI-PubMed.27428445.s38.e0" e2="DDI-PubMed.27428445.s38.e1" /></sentence><sentence text="  • No difference in mortality was observed between residents exposed to DDDIs and residents not exposed to DDDIs" /><sentence text="" /></document>